Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dbv Technologies ADR (NQ: DBVT )

0.7612 -0.0172 (-2.21%)
Streaming Delayed Price Updated: 3:59 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Dbv Technologies ADR

< Previous 1 2 3 Next >
Healthcare and Biotech Stocks to Watch: MODD, CRDL, DBVT, VRAX
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Participate in Upcoming ACAAI 2024 Congress
From DBV Technologies S.A.
Via GlobeNewswire
Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From DBV Technologies S.A.
Via GlobeNewswire
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024
From DBV Technologies S.A.
Via GlobeNewswire
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From DBV Technologies S.A.
Via GlobeNewswire
Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Announces Plan to Implement ADS Ratio Change
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Participate in Upcoming EAACI 2024 Congress
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Announces Plan to Implement ADS Ratio Change
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Announces Results of its 2024 Combined General Meeting
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Participate in Upcoming Investor Conferences
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Reports First Quarter 2024 Financial Results and Business Update
From DBV Technologies S.A.
Via GlobeNewswire
Combined General Meeting of May 16, 2024
From DBV Technologies S.A.
Via GlobeNewswire
Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Reports Full Year 2023 Financial Results and Business Update
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Participate in Upcoming AAAAI 2024 Congress
From DBV Technologies S.A.
Via GlobeNewswire
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
From DBV Technologies S.A.
Via GlobeNewswire
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers
From DBV Technologies S.A.
Via GlobeNewswire
Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Present New Data at ACAAI 2023
From DBV Technologies S.A.
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.